Please assess the completion status of the following clinical trial:

Trial Title: Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented COVID-19 infection (confirmed by NPS positive PCR for SARS-CoV-2) with mild symptoms not requiring hospitalization~* First NPS ≤4 days (96 hours) since onset of symptoms~* Randomization ≤72 hours since first NPS~* Adult Males aged ≥ 50 years~* Indication for outpatient treatment but at high risk for complications, at least 1 risk factor (age ≥ 65 years, hypertension, diabetes, cardiovascular disease, active malignancy, COPD)~* WHO performance status 0-1~* Adequate hematologic values: haemoglobin ≥ 100 g/L, neutrophils ≥ 1.0 x 10(9)/L, platelets ≥ 150 x 10(9)/L.~* Adequate hepatic function: ALT and AST ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN (exception if Gilbert's syndrome ≤ 2.5 x ULN)~* Adequate renal function: calculated creatinine clearance ≥ 50 mL/min according to the formula of Cockcroft-Gault~* Patient is able to swallow the trial drugs and to comply with trial requirements~* Patient agrees not to father a child during participation in the trial and for 3 months thereafter~Exclusion Criteria:~* Female sex~* Moderate to severe COVID-19 symptoms requiring hospitalization~* Patients requiring inpatient treatment~* Concurrent antiviral drugs or ongoing interventional clinical trial or any off label drug for COVID-19~* Patients with ongoing prostate cancer treatment~* Clinically significant cardiovascular disease including:~  * Myocardial infarction within 6 months prior to registration,~ * Uncontrolled angina within 3 months prior to registration,~ * Congestive heart failure NYHA class III or VI~ * QTc interval \> 480 ms~ * History of clinically significant ventricular arrhythmias (e.g. ventricular tachycardia, ventricular fibrillation, torsades de pointes)~ * History of Mobitz II second or third degree heart block without a permanent pacemaker in place~ * Uncontrolled hypertension as indicated by systolic blood pressure \> 170 mmHg or diastolic blood pressure \> 105 mmHg~ * Deep venous thrombosis or pulmonary embolism within 6 months~ * History of cerebrovascular disease~* Severe concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrolment.~* Known history of HIV, hepatitis B, hepatitis C~* Known history of seizures or any conditions that may predispose to seizure. History of loss of consciousness or ischemic cerebrovascular attack within 12 months prior to registration~* Concurrent anticoagulation with rivaroxaban or warfarin. Concomitant and continuous use of systemic corticosteroids exceeding 10 mg/day of prednisone or a dose equivalent corticosteroid within 14 days before registration.~* Known hypersensitivity to Enzalutamide or hypersensitivity to any of its components~* Any concomitant drugs contraindicated for use with Enzalutamide according to the Swissmedic approved product information~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol and follow-up.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Xtandi®) (Type: EXPERIMENTAL): Interventional treatment
- Standard of care (SOC) (Type: ACTIVE_COMPARATOR): Supportive treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).